Walmart Adds Free GLP-1 Drugs, Expands Benefits for 2027

Walmart will eliminate out-of-pocket costs for certain GLP-1 medications used to treat Type 2 diabetes for eligible employees starting in 2027, a move that places the nation’s largest private employer at the center of an escalating corporate battle over metabolic disease coverage.

The decision arrives as U.S. employers face unprecedented pressure from the surging demand for glucagon-like peptide-1 receptor agonists. While drugs such as semaglutide and tirzepatide dominate headlines for their weight-loss applications, they were initially approved and remain critical therapies for glycemic control in Type 2 diabetes. By covering these specific formulations at no cost, Walmart is targeting chronic disease management rather than entering the more expensive and heavily debated arena of employer-sponsored obesity treatment. Most large U.S. employers have resisted covering GLP-1s for weight loss due to annual costs that frequently exceed $10,000 per patient, though pharmacy benefit managers report that diabetes indications are increasingly driving overall plan spend.

Chief People Officer Donna Morris outlined the broader benefits overhaul in an Oct. 13 letter to staff. Beyond the GLP-1 expansion, Walmart is adding more than 250 prescription drugs to its zero-cost formulary under most medical plans, including insulin products and inhalers. The retailer currently employs approximately 1.6 million workers in the United States, making its formulary decisions a significant market signal for pharmaceutical pricing and pharmacy benefit negotiations nationwide.

The expanded drug coverage coincides with a premium increase for the company’s entry-level health insurance plan. Monthly costs for the base tier will rise by $3 per month, or $1.50 per biweekly pay period, bringing the total to $39.80. Even with the hike, Walmart’s starting premium remains significantly below the national average for single-coverage employer-sponsored health insurance, which the Kaiser Family Foundation reported surpassed $115 per month in recent annual surveys. Employers across the retail and logistics sectors have struggled to balance rising healthcare expenditures with wage pressures and thin operating margins.

Walmart is simultaneously deepening its investments in specialized care. The retailer’s Centers of Excellence program now covers evaluations and treatment reviews for multiple sclerosis, Parkinson’s disease and amyotrophic lateral sclerosis (ALS). Eligible employees enrolled in most medical plans can access these specialist consultations at Mayo Clinic or Cleveland Clinic without out-of-pocket expenses. Direct-to-center-of-excellence models have gained traction among mega-cap employers over the past decade as a strategy to bypass fragmented local care networks, reduce misdiagnoses and lower long-term surgical or hospitalization costs for complex neurological conditions.

New family support policies also take effect before the end of the year. Starting Nov. 17, employees whose children require neonatal intensive care unit admission will receive up to 12 weeks of dedicated paid leave. This benefit operates independently of existing maternity, parental and general paid leave allowances, allowing workers to stack the time. NICU-specific leave remains relatively rare in the U.S. corporate sector, where standard parental leave policies often fail to account for the prolonged hospitalizations associated with premature births or severe neonatal complications.

Existing programs remain intact, including 20 fully covered mental health therapy sessions annually and up to $20,000 in financial assistance for fertility treatments, adoption or surrogacy. Mental health parity requirements under federal law mandate coverage structures, but fully subsidized session counts of this size are typically reserved for salaried corporate roles rather than hourly retail workforces.

The changes are being implemented during Walmart’s annual benefits enrollment window, which closes Nov. 6.